

SMITH & NEPHEW PLC

12 July 2024

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

On 11 July 2024, Smith & Nephew plc (the "Company") received notification of the following transactions as detailed below.

Reason for the notification	
Initial notification /Amendment	Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
Name	Smith & Nephew plc
LEI	213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
Description of the financial instrument, type of instrument	Smith & Nephew plc SPON ADR American Depository Shares (ADS)
Identification code	ISIN: US83175M2052
Nature of the transaction	Purchase of American Depository Shares as participants of the Company's Employee Stock Purchase Plan
Date of Transaction	2024-07-5
Place of Transaction	New York Stock Exchange

Name	Director / PDMR	Price (\$)	Volume	Aggregated information
Deepak Nath (Chief Executive Officer)	Director	21.06	465.54938	N/A Single Transaction
Paul Connolly (President, Global Operations)	PDMR	21.06	465.54938	N/A Single Transaction
Craig Gaffin (President, Global Orthopaedics)	PDMR	21.06	465.54938	N/A Single Transaction
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer)	PDMR	21.06	108.48433	N/A Single Transaction
Scott Schaffner (President, Sports Medicine)	PDMR	21.06	261.92498	N/A Single Transaction

Helen Barraclough
General Counsel and Company Secretary
Smith & Nephew plc

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLFERDAILLIS